Agenda

Date and TimeTitle
Mar 17, 2022
3:45pm - 4:45pm (Eastern)
Implementing precision oncology in the clinic: Diagnostic challenges and best practices

Webinar Objectives: Discuss the optimal diagnostic techniques and guidelines to identify actionable biomarker driven NSCLC to support treatment decisions

Discuss the role of the Tumour Board / Multi Disciplinary Team (MDT) in translating clinical evidence into clinical practice to optimize outcomes for patients. 

*Please note, Q&A and Polling is not active for the Pre-recorded session.

Sponsored by Lilly Oncology

This is a NON CE/CME Presentation.

 

 

Mar 17, 2022
6:00pm - 7:29pm (Eastern)
Session I: Targeted Therapy in NSCLC 1

6:00 pm ET | Introduction
Christine Lovly MD, PhD

6:05 pm ET | Biomarker Testing in Lung Adenocarcinoma
Marc Ladanyi, MD

6:20 pm ET | First Line Therapy for ​Patients With EGFR, KRAS, or BRAF Mutations
Kathryn C. Arbour, MD

6:35 pm ET | First Line Therapy for ALK, ROS1, RET, and NTRK
Lyudmila A. Bazhenova, MD

6:50 pm ET | Supportive Care and Pharmacology Considerations
R. Donald Harvey, PharmD​

7:05 pm ET | Q&A/Panel Discussion
Christine Lovly MD, PhD
Marc Ladanyi, MD
Kathryn C. Arbour, MD
Lyudmila A. Bazhenova, MD
R. Donald Harvey, PharmD​

Supported by an independent educational grant from AstraZeneca Pharmaceuticals LP

Supported by an independent educational grant from Daiichi Sankyo

Supported by an independent educational grant from Exact Sciences

Supported by an independent educational grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC

Supported by an independent educational grant from Novartis Oncology

Supported by an independent educational grant from Novocure®

Supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals

 

ACCREDITATION INFORMATION

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

For Physicians
Medscape, LLC designates this live activity for a maximum of 1.25 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 1.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.25 contact hours in the area of pharmacology.

For Pharmacists
Medscape designates this continuing education activity for Knowledge-based 1.25 contact hours and 1.25 CEUs. See individual session Universal Activity number JA0007105-0000-22-025-L01-P.

Mar 17, 2022
7:29pm - 7:30pm (Eastern)
Break
Mar 17, 2022
7:30pm - 9:00pm (Eastern)
Session II: Targeted Therapy in NSCLC 2

7:30 pm ET | Introduction

7:35 pm ET | Understanding and Tackling Resistance to EGFR, BRAF​ and KRAS ​ in NSCLC

7:53 pm ET | Addressing Resistance in ALK, ROS1, RET, and TRK​

8:08 pm ET | Management of CNS Disease in NSCLC: CNS Tropism, Monitoring, and Treatment Options

8:25 pm ET | Emerging Targets​: NRG1, HER3, TROP2

8:39 pm ET | Q&A/Panel Discussion

Supported by an independent educational grant from AstraZeneca Pharmaceuticals LP
Supported by an independent educational grant from Daiichi Sankyo
Supported by an independent educational grant from Exact Sciences
Supported by an independent educational grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC
Supported by an independent educational grant from Novartis Oncology
Supported by an independent educational grant from Novocure®
Supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals

 

ACCREDITATION INFORMATION

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians
Medscape, LLC designates this live activity for a maximum of 1.25 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 1.25 contact hour(s) of nursing continuing professional development for RNs and APNs; final contact hours in the area of pharmacology will be posted on the conference platform.

For Pharmacists
Medscape designates this continuing education activity for Knowledge-based 1.25 contact hours and .125 CEUs. See individual session Universal Activity number JA0007105-0000-22-026-L01-P.

Mar 18, 2022
11:00am - 12:02pm (Eastern)
Approaches to the Management of Small Cell Lung Cancer

A patient-focused educational session presented by the GO2 Foundation for Lung Cancer

Sponsored by the GO2 Foundation for Lung Cancer

This is a Non CE/CME Presentation.

Mar 18, 2022
12:45pm - 1:20pm (Eastern)
Exploring a Treatment Option for Patients With Previously Treated Metastatic Small Cell Lung Cancer

Summary

Learning Objectives:

This program will explore:

o An overview of unmet needs in SCLC

o Current treatment guidelines for SCLC

o Efficacy and safety findings from a study of an FDA-approved treatment for previously treated metastatic SCLC

o Considerations for dosing, administration, and patient counseling

Sponsored by Jazz Pharmaceuticals
This is a Non CE/CME Presentation.

Mar 18, 2022
2:00pm - 2:30pm (Eastern)
Please join us to learn about an FDA-approved first line monotherapy option in advanced NSCLC

Program Description: This program will review: Historical clinical trial eligibility considerations in advanced NSCLC Clinical evidence, safety profile, and post-hoc and exploratory analyses from one of the largest advanced NSCLC clinical trials conducted to date.

Sponsored by Regeneron & Sanofi Genzyme

This is a Non CE/CME Presentation.

Mar 18, 2022
2:45pm - 3:00pm (Eastern)
Break | Visit the Exhibit Hall

Please take a moment to visit the Exhibit Hall.

Mar 18, 2022
3:00pm - 4:35pm (Eastern)
Session III: Immunotherapy in NSCLC

3:00 pm ET | Introduction
Charu Aggarwal, MD, MPH

3:05 pm ET | Immunotherapy and IO-IO Combination Therapy in Frontline Metastatic Management
Hossein Borghaei, DO, MS

3:19 pm ET | Chemo-IO Combination Therapy in Frontline Metastatic Management
Marina Chiara Garassino, MD

3:35 pm ET | Emerging Immunotherapies and Biomarkers in NSCLC
Melina Elpi Marmarelis, MD, MSCE​

3:46 pm ET | Management of Immunotherapy Toxicities and Building a Program With Partnerships ​
Kerry Reynolds, MD

4:00 pm ET | Clinical Cases: Debating the Pros and Cons
Moderator: Charu Aggarwal, MD, MPH
Hossein Borghaei, DO, MS
Marina Chiara Garassino, MD
Melina Elpi Marmarelis, MD, MSCE​
Kerry Reynolds, MD

4:17 pm ET | Q&A/Panel Discussion
Charu Aggarwal, MD, MPH
Hossein Borghaei, DO, MS
Marina Chiara Garassino, MD
Melina Elpi Marmarelis, MD, MSCE​
Kerry Reynolds, MD

Supported by an independent educational grant from AstraZeneca Pharmaceuticals LP
Supported by an independent educational grant from Daiichi Sankyo
Supported by an independent educational grant from Exact Sciences
Supported by an independent educational grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC
Supported by an independent educational grant from Novartis Oncology
Supported by an independent educational grant from Novocure®
Supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals

 

ACCREDITATION INFORMATION

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

For Physicians
Medscape, LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 1.25 contact hour(s) of nursing continuing professional development for RNs and APNs; final contact hours in the area of pharmacology will be posted on the conference platform.

For Pharmacists
Medscape designates this continuing education activity for Knowledge-based 1.25 contact hours and .125 CEUs. See individual session Universal Activity number JA0007105-0000-22-027-L01-P.

Mar 18, 2022
4:35pm - 4:45pm (Eastern)
Break | Visit the Exhibit Hall

Please take a moment to visit the Exhibit Hall.

Mar 18, 2022
4:45pm - 5:34pm (Eastern)
Session IV: Management of SCLC

4:45 pm ET | Introduction
Ticiana Leal, MD

4:50 pm ET | Innovative Approaches to First-Line Management of SCLC
Anne Chiang, MD, PhD

5:02 pm ET | What’s Next in Second-Line Management of SCLC?
Jacob Sands, MD

5:12 pm ET | The Role of Radiation Therapy in Small Cell Lung Cancer​
Salma Jabbour, MD

5:24 pm ET | Q&A/Panel Discussion
Moderator: Ticiana Leal, MD
Anne Chiang, MD, PhD
Jacob Sands, MD
Salma Jabbour, MD

Supported by an independent educational grant from AstraZeneca Pharmaceuticals LP
Supported by an independent educational grant from Daiichi Sankyo
Supported by an independent educational grant from Exact Sciences
Supported by an independent educational grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC
Supported by an independent educational grant from Novartis Oncology
Supported by an independent educational grant from Novocure®
Supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals

 

ACCREDITATION INFORMATION

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians
Medscape, LLC designates this live activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded .75 contact hour(s) of nursing continuing professional development for RNs and APNs; final contact hours in the area of pharmacology will be posted on the conference platform.

For Pharmacists
Medscape designates this continuing education activity for Knowledge-based .75 contact hours and .075 CEUs. See individual session Universal Activity number JA0007105-0000-22-028-L01-P.

Mar 18, 2022
5:34pm - 5:45pm (Eastern)
Break | Visit the Exhibit Hall

Please take a moment to visit the Exhibit Hall.

Mar 18, 2022
5:45pm - 6:35pm (Eastern)
Session V: Mesothelioma

5:45 pm ET | Introduction
Ibiayi Dagogo-Jack, MD

5:50 pm ET | Immunotherapy in Mesothelioma
Patrick Forde, MBBCh

5:57 pm ET | Clinical Case: Experts Discuss First-Line Management of Mesothelioma
Jessica Donington, MD
Ibiayi Dagogo-Jack, MD
Marjorie Zauderer, MD
Patrick Forde, MBBCh

6:09 pm ET | Emerging Targets in Mesothelioma
Marjorie Zauderer, MD

6:21 pm ET | Q&A/Panel Discussion
Moderator: Ibiayi Dagogo-Jack, MD
Jessica Donington, MD
Marjorie Zauderer, MD
Patrick Forde, MBBCh

6:31 pm ET | Day 2 Closing Remarks
Lecia V. Sequist, MD, MPH

Supported by an independent educational grant from AstraZeneca Pharmaceuticals LP
Supported by an independent educational grant from Daiichi Sankyo
Supported by an independent educational grant from Exact Sciences
Supported by an independent educational grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC
Supported by an independent educational grant from Novartis Oncology
Supported by an independent educational grant from Novocure®
Supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals

 

ACCREDITATION INFORMATION

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians
Medscape, LLC designates this live activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded .75 contact hour(s) of nursing continuing professional development for RNs and APNs; final contact hours in the area of pharmacology will be posted on the conference platform.

For Pharmacists
Medscape designates this continuing education activity for Knowledge-based .75 contact hours and .075 CEUs. See individual session Universal Activity number JA0007105-0000-22-029-L01-P.

Mar 19, 2022
8:45am - 9:28am (Eastern)
Exkivity (Mobocertinib) - The First Oral Therapy for EGFR Exon20 Insertion+ mNSCLC Patients Post Platinum-Based Chemotherapy

Sponsored by Takeda
This is a Non CE/CME Presentation.

Mar 19, 2022
9:45am - 10:00am (Eastern)
Break | Visit the Exhibit Hall

Please take a moment to visit the Exhibit Hall.

Mar 19, 2022
10:00am - 11:30am (Eastern)
Session VI: Early-Stage and Locally Advanced NSCLC Management

10:00 am ET | Introduction
Nathan Pennell, MD, PhD

10:04 am ET | Personalizing Perioperative Therapy in Resectable NSCLC​
Jamie E. Chaft, MD

10:15 am ET | Locally Advanced NSCLC Management
Anne S. Tsao, MD, MBA

10:33 am ET | Early-Stage NSCLC​: The Surgical Perspective
David Tom Cooke, MD, FACS

10:46 am ET | Radiation Oncology Advances in Management of Early Stage/Locally Advanced NSCLC​
Kristin A. Higgins, MD

11:00 am ET | Patient Advocate Interview
Jill Feldman, MA, Patient Advocate
Nathan Pennell, MD, PhD

11:11 am ET | Q&A/Panel Discussion
Moderator: Nathan Pennell, MD, PhD
Jamie E. Chaft, MD
Anne S. Tsao, MD, MBA
David Tom Cooke, MD, FACS
Kristin A. Higgins, MD

Supported by an independent educational grant from AstraZeneca Pharmaceuticals LP
Supported by an independent educational grant from Daiichi Sankyo
Supported by an independent educational grant from Exact Sciences
Supported by an independent educational grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC
Supported by an independent educational grant from Novartis Oncology
Supported by an independent educational grant from Novocure®
Supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals

 

ACCREDITATION INFORMATION

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians
Medscape, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 1.5 contact hour(s) of nursing continuing professional development for RNs and APNs; final contact hours in the area of pharmacology will be posted on the conference platform.

For Pharmacists
Medscape designates this continuing education activity for Knowledge-based 1.5 contact hours and .15 CEUs. See individual session Universal Activity number JA0007105-0000-22-030-L01-P)..

Mar 19, 2022
11:30am - 11:45am (Eastern)
Break | Visit the Exhibit Hall

Please take a moment to visit the Exhibit Hall.

Mar 19, 2022
11:45am - 12:45pm (Eastern)
Session VII: Lung Cancer Screening and Early Detection

11:45 am ET | Introduction
Lecia V. Sequist, MD, MPH

11:50 am ET | Barriers and Opportunities to Advance Equity in Lung Cancer Screening
Efrén J. Flores, MD

12:01 pm ET | Incidental Pulmonary Nodules: Uncharted Territory?
Raymond Osarogiagbon, MBBS, FACP

12:12 pm ET | Liquid Biopsies in Early Detection of Lung Cancer​
Lecia V. Sequist, MD, MPH

12:23 pm ET | Patient Advocate Interview​
Lecia V. Sequist, MD, MPH
Terri Ann DiJulio, Patient Advocate

12:34 pm ET | Q&A/Panel Discussion
Moderator: Lecia V. Sequist, MD, MPH
Raymond Osarogiagbon, MBBS, FACP
Efrén J. Flores, MD
Terri Ann DiJulio, Patient Advocate

Supported by an independent educational grant from AstraZeneca Pharmaceuticals LP
Supported by an independent educational grant from Daiichi Sankyo
Supported by an independent educational grant from Exact Sciences
Supported by an independent educational grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC
Supported by an independent educational grant from Novartis Oncology
Supported by an independent educational grant from Novocure®
Supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals

 

ACCREDITATION INFORMATION

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians
Medscape, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs; final contact hours in the area of pharmacology will be posted on the conference platform.

For Pharmacists
Medscape designates this continuing education activity for Knowledge-based 1.0 contact hours and .10 CEUs. See individual session Universal Activity number JA0007105-0000-22-031-L01-P.

Mar 19, 2022
12:45pm - 1:35pm (Eastern)
Session VIII: Clinical Case Discussion

12:45 pm ET | Clinical Case Discussion
Moderator: Lecia V. Sequist, MD, MPH
Stephen Liu, MD

Ticiana Leal, MD
Ibiayi Dagogo-Jack, MD
Charu Aggarwal, MD, MPH
Nathan Pennell, MD, PhD

1:35 pm ET | Closing Remarks/Conference Adjourns
Lecia V. Sequist, MD, MPH

Supported by an independent educational grant from AstraZeneca Pharmaceuticals LP
Supported by an independent educational grant from Daiichi Sankyo
Supported by an independent educational grant from Exact Sciences
Supported by an independent educational grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC
Supported by an independent educational grant from Novartis Oncology
Supported by an independent educational grant from Novocure®
Supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals

 

ACCREDITATION INFORMATION

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians
Medscape, LLC designates this live activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Mar 22, 2022
7:30pm - 8:27pm (Eastern)
Encore Presentation: Implementing precision oncology in the clinic: Diagnostic challenges and best practices

Webinar Objectives: Discuss the optimal diagnostic techniques and guidelines to identify actionable biomarker driven NSCLC to support treatment decisions

Discuss the role of the Tumour Board / Multi Disciplinary Team (MDT) in translating clinical evidence into clinical practice to optimize outcomes for patients. 

*Please note, Q&A and Polling is not active for the Pre-recorded session.

Sponsored by Lilly Oncology

This is a NON CE/CME Presentation.